文献速递前列腺癌

表观遗传学检测预测非裔美国男性重复前列腺穿刺结果

Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.
PubMed 文献 · Urology · 2018-04-13

本研究在211名非裔美国男性中评估ConfirmMDx表观遗传学检测(GSTP1、APC、RASSF1)对重复前列腺穿刺结果的预测价值。重复穿刺检出前列腺癌38%(81/211),其中Gleason≤6占67%、≥7占33%。检测前列腺癌的敏感度74.1%、特异度60.0%,与非裔美国男性为主的前期研究等效;检出Gleason≥7的敏感度78%、特异度53%。

要点

  • ConfirmMDx在非裔美国男性中验证,敏感度74.1%、特异度60.0%预测重复穿刺前列腺癌。
  • 对Gleason≥7前列腺癌的敏感度78%、特异度53%,阴性预测值94.2%。
  • 检测性能与以白人为主人群的前期研究一致,可用于非裔美国男性风险分层。

核心结论

  • ConfirmMDx表观遗传学检测在非裔美国男性中成功验证,可评估重复穿刺必要性,结果与以白人为主人群的研究一致。

研究设计与样本

  • 研究纳入来自美国7个泌尿中心的211名非裔美国男性,均在初次阴性穿刺后30个月内接受12针经直肠超声引导重复穿刺。
  • 对初次阴性穿刺的所有穿刺芯使用ConfirmMDx检测GSTP1、APC和RASSF1表观遗传学生物标志物。

主要发现

  • 重复穿刺时,130/211(62%)未检出前列腺癌,81/211(38%)诊断为前列腺癌。
  • 前列腺癌患者中,54例(67%)为Gleason评分≤6,27例(33%)为Gleason评分≥7。
  • 检测前列腺癌的敏感度为74.1%、特异度为60.0%,与前期研究等效(P=.235和.697)。
  • 检测Gleason评分≥7前列腺癌的敏感度为78%、特异度为53%。
  • 检测所有前列腺癌和Gleason评分≥7前列腺癌的阴性预测值分别为78.8%和94.2%。

临床怎么用

  • ConfirmMDx可用于非裔美国男性初次穿刺阴性后的风险分层,辅助判断是否需要重复穿刺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. MATERIALS AND METHODS: The study population consisted of 211 AA men from 7 urology centers across the United States; all of whom were undergoing 12-core transrectal ultrasound-guided repeat biopsy within 30 months from a negative index biopsy. All biopsy cores from the negative index biopsy were profiled for the epigenetic biomarkers GSTP1, APC, and RASSF1 using ConfirmMDx for Prostate Cancer (MDxHealth, Irvine, CA). RESULTS: Upon repeat biopsy, 130 of 211 subjects (62%) had no prostate cancer (PCa) detected and 81 of 211 (38%) were diagnosed with PCa. Of the subjects with PCa, 54 (67%) were diagnosed with Gleason score (GS) ≤6 PCa and 27 (33%) with GS ≥7 disease. For detection of PCa at repeat biopsy, ConfirmMDx sensitivity was 74.1% and specificity was 60.0%, equivalent to prior studies (P = .235 and .697, respectively). For detection of GS ≥7 PCa, sensitivity was 78% and specificity was 53%. The negative predictive values for detection of all PCa and GS ≥7 PCa were 78.8% and 94.2%, respectively. CONCLUSION: In this group of AA men, we successfully validated an epigenetic assay to assess the need for repeat biopsy. Results were consistent with previous studies from predominantly Caucasian populations. Therefore, the ConfirmMDx assay is a useful tool for risk stratification of AA men who had an initial negative biopsy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Waterhouse RL, Van Neste L, Moses KA, et al. Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. Urology. 2018. PMID: 29660369. doi:10.1016/j.urology.2018.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。